Allergic Conjunctivitis and Quality of Life Directly Correlate in Pediatric Patients
Allergic conjunctivitis (AC) is a common allergic condition that occurs frequently in pediatric patients. In a publication in JAMA Ophthalmology, researchers attempted to explore the impact of AC symptoms on overall patient/caregiver quality of life. Read more.

First Oral Anticoagulant for Pediatric Patients
The FDA approved dabigatran etexilate (Pradaxa) oral pellets to treat pediatric patients aged 3 months to younger than age 12 years with venous thromboembolism (VTE) directly after they have been treated with a blood thinner given by injection for at least 5 days. The FDA also approved Pradaxa oral pellets to prevent recurrent clots among patients in the same age group who completed their first VTE treatment. Read more.

Pros and Cons of Pharmacy Compounding
There are numerous pros to the use of compounded medications. They allow for customized, flexible, and precise dosing and are necessary when an FDA-approved drug product is not available or appropriate or for which the usual strength or route of delivery must be altered. At the same time, serious patient illnesses and death have been linked to poor-quality compounding drugs. Read more.